ArticleCurrent oncology (Toronto, Ont.)2022

Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies.

Ioannis A VoutsadakisPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.